# Saracatinib in Treating Patients With Prostate Cancer

> **NCT01267266** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 31 (actual)

## Conditions studied

- Hormone-resistant Prostate Cancer
- Recurrent Prostate Cancer
- Stage IV Prostate Cancer

## Interventions

- **DRUG:** saracatinib
- **OTHER:** hydrocortisone/placebo

## Key facts

- **NCT ID:** NCT01267266
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-12
- **Primary completion:** 2012-09
- **Final completion:** 2013-11
- **Target enrollment:** 31 (ACTUAL)
- **Why stopped:** Per protocol, study was terminated due to low rate of randomized patients.
- **Last updated:** 2015-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01267266

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01267266, "Saracatinib in Treating Patients With Prostate Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01267266. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*